



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/553,633	11/07/2006	Songtao Shi	4239-81540-05	4649
36218	7590	06/10/2011	EXAMINER	
KLARQUIST SPARKMAN, LLP (OTT-NIH) 121 S.W. SALMON STREET SUITE #1600 PORTLAND, OR 97204-2988			FALK, ANNE MARIE	
			ART UNIT	PAPER NUMBER
			1632	
			NOTIFICATION DATE	DELIVERY MODE
			06/10/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

tanya.harding@klarquist.com
docketing@klarquist.com

Office Action Summary	Application No.	Applicant(s)
	10/553,633	SHI ET AL.
	Examiner	Art Unit
	Anne-Marie Falk, Ph.D.	1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 21 January 2011.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 59-65,67,68,71-78,80-86,88-90,92-102,104-106,108,110 and 111 is/are pending in the application.
- 4a) Of the above claim(s) 67,68,71-78,80-86,88-90,92-102 and 108 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 59-65,104-106, 110 and 111 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 19 October 2005 is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)	
1) <input type="checkbox"/> Notice of References Cited (PTO-892) 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ . 5) <input type="checkbox"/> Notice of Informal Patent Application 6) <input type="checkbox"/> Other: _____.

DETAILED ACTION

The finality of the prior Office action issued on May 3, 2011 is hereby withdrawn and the action is reissued herein as a Non-Final Rejection. This action replaces the Office action mailed May 3, 2011.

The amendment filed January 21, 2011 (hereinafter referred to as “the response”) has been entered. Claims 59-65, 67, 78, 86, 89, 90, 104, 105, 106, and 108 have been amended. Claims 103, 107, and 109 have been cancelled and Claims 110 and 111 have been newly added.

Accordingly, Claims 59-65, 67, 68, 71-78, 80-86, 88-90, 92-102, 104-106, 108, 110 and 111 are pending in the instant application.

The elected invention is drawn to a dental pulp multipotent stem cell.

Claims 67, 68, 71-78, 80-86, 88-90, 92-102, and 108 remain withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on December 9, 2009.

Accordingly, Claims 59-65, 104-106, 110, and 111 are examined herein.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 21, 2011 has been entered.

The objection to Claim 103 under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim, is **withdrawn** in view of the cancellation of the claim.

The Declaration of Dr. Akiyama has been fully considered and is accepted as showing that a biological deposit was made and that the material deposited therein was the biological material identified in the patent application as originally filed.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

New Matter

Claims 59-65, 104-106 stand rejected and Claims 110 and 111 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The amended claims and newly added claims include new matter.

MPEP 2163.03(I) provides that an amendment to the claims or the addition of a new claim must be supported by the description of the invention in the application as filed. *In re Wright*, 866 F.2d 422, 9 USPQ2d 1649 (Fed. Cir. 1989). Applicants should specifically point out the support for any amendments made to the claims. MPEP 2163 states that new or amended claims which introduce elements or limitations which are not supported by the as-filed disclosure violate the written description requirement.

See, e.g., *In re Lukach*, 442 F.2d 967, 169 USPQ 795 (CCPA 1971) and *In re Smith*, 458 F.2d 1389,

1395, 173 USPQ 679, 683 (CCPA 1972). MPEP 714.02 notes that Applicant should also specifically point out the support for any amendments made to the disclosure. See also MPEP 2163.06(I), which notes that Applicants should specifically point out the support for any amendments made to the disclosure.

In the amendment filed April 1, 2010, the claims were amended to add the limitation “wherein the isolated human postnatal dental pulp multipotent stem cell can proliferate to over 140 population doublings.” In the amendment filed January 21, 2011, Claim 59 was further amended to add the limitation “wherein stem cells in the population induce the formation of bone when transplanted *in vivo*.” Accordingly, Claim 59 is directed to a CD146-positive cell that can proliferate to over 140 population doublings and also possesses the ability to induce the formation of bone when transplanted *in vivo*. However, the specification does not describe a CD146-positive cell that can proliferate to over 140 population doublings. On the contrary, the specification only describes a mixed population of cells (SHED) that can proliferate to over 140 population doublings. Likewise, the specification does not describe a CD146-positive cell that has the ability to induce the formation of bone when transplanted *in vivo*. On the contrary, the specification only describes clonal cells that have the ability to induce the formation of bone when transplanted *in vivo*, but these clones are not defined by any particular cell markers (page 28, lines 5-11).

In the reply filed April 1, 2010, as support for the amendment reciting 140 population doublings, Applicants pointed to the specification at page 7, lines 10-15 and Figure 5. However, the cited section clearly describes a mixed population of cells, designated as “SHED.” The assessment of proliferation in terms of population doublings was carried out using this mixed population of cells (SHED). Notably, the specification does not provide an assessment of the proliferation of any particular cell type present within the mixed population. Thus, the rate of proliferation of the multipotent stem cell that is identified as residing within this mixed population of cells is unknown. Accordingly, the specification fails to describe

a multipotent stem cell that can proliferate to over 140 population doublings. Instead, the specification describes a mixed population of cells (SHED) which can proliferate to over 140 population doublings. The proliferative capacity of any cell type within the mixed population is unknown. Thus, there is no evidence that a CD146-positive cell can proliferate to over 140 population doublings. Accordingly, there is no evidence that Applicants were in possession of a CD146-positive cell that can proliferate to over 140 population doublings.

Newly added Claims 110 and 111 depend from Claim 59 and therefore incorporate all the limitations of independent Claim 59. Although Claim 110 recites an ATCC deposit number, the claim is not directed to the deposited cells *per se*, but instead is only directed to cells that have the characteristics of the deposited cells in addition to the properties recited in the limitations of Claim 59. As discussed above, the specification does not describe a population of cells having the properties recited in Claim 59. Claim 111 is directed to a clonal cell isolated from the isolated population of human postnatal deciduous dental pulp multipotent stem cells of Claim 59. However, the specification does not describe a clonal cell that can proliferate to over 140 population doublings, nor does it describe a clonal cell that expresses CD146. Thus, the specification clearly fails to describe a CD146-positive clonal cell that can proliferate to over 140 population doublings.

As amended, Claim 59 is directed to a CD146-positive multipotent stem cell that can proliferate to over 140 population doublings and can differentiate into a neural cell, an adipocyte, or an odontoblast, and further possesses the ability to induce the formation of bone when transplanted *in vivo*. However, there is no description of a CD146-positive cell that can proliferate to over 140 population doublings. While the specification does disclose that SHED were able to proliferate to over 140 population doublings (page 7, line 14), the specification makes it clear that SHED is a mixed population of cells (pages 27-28). See for example, the specification at page 8, lines 10-17, which discloses that only 25% of SHED clones were capable of generating dentin *in vivo*. At page 7, lines 17-21, the specification discloses that SHED

expressed STRO-1 and CD146 and that FACS analysis of *ex vivo* expanded SHED showed that SHED contained approximately 9% STRO-1-positive cells. The specification is silent as to the percentage of SHED expressing CD146. However, there is no disclosure of CD146-positive cells that have the potential to undergo 140 population doublings. Only the mixed population of SHED is described as having the ability to proliferate to over 140 population doublings (page 7, lines 14-15 and Figure 5H).

Likewise, with regard to Claim 61, the specification does not describe a STRO-1-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe an ALP-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a matrix extracellular phosphoglycoprotein-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe an bFGF-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe an endostatin-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a cell that expresses a combination of these proteins and that can also proliferate to over 140 population doublings.

Likewise, with regard to Claim 62, the specification does not describe a CBFA1-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe an MEPE-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe an BSP-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe an DSPP-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a cell that expresses a combination of these proteins and that can also proliferate to over 140 population doublings.

Likewise, with regard to Claim 63, the specification does not describe a osterix-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe an osteocalcin-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a

Art Unit: 1632

cell that expresses a combination of these proteins and that can also proliferate to over 140 population doublings.

Likewise, with regard to Claim 64, the specification does not describe a nestin-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe an β III tubulin-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a glutamic acid decarboxylase-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a neuronal nuclei-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a glial fibrillary acidic protein-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a neurofilament M-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a 2'3'-cyclic nucleotide-3'-phosphodiesterase-positive cell that can proliferate to over 140 population doublings. Nor does the specification describe a cell that expresses a combination of these proteins and that can also proliferate to over 140 population doublings.

Given the many dependent claims to isolated human postnatal deciduous dental pulp stem cells, Claim 59 appears to cover a wide variety of stem cells expressing distinct sets of markers. Accordingly, Claim 59 is further rejected insofar as it encompasses the various cell types recited in Claims 61-65 because the specification fails to describe all the cell types encompassed by Claim 59. The dependent claims appear to be directed to various subsets of stem cells that fall within the broad independent claim (i.e., Claim 59), but there is no description of distinct multipotent stem cells that are CD146-positive and that can proliferate to over 140 population doublings.

Since the as-filed specification does not describe the subject matter of Claim 59 and the various cell types recited in the dependent claims, claims directed to subject matter not disclosed in the originally filed specification cannot be introduced after the application filing date. Such a claim raises an issue of new matter. Given the new limitations added by amendment, the specification would have to provide

support for the multipotent stem cell of Claim 59, in its broadest sense, and multiple distinct cell types as set forth in the dependent claims. However, the specification does not provide broad support, nor does it provide narrower support for cells expressing the various proteins recited in the claims and also having the ability to proliferate to over 140 population doublings. Thus, the as-filed specification does not provide adequate support for the amended claims and newly added claims.

Thus, the amended claims and newly added claims include new matter.

At page 10 of the response, Applicants assert that clonal cell populations of SHED cells are described in the specification at page 27, line 29 and that all of these clonal populations of cells induce bone formation upon transplantation. Applicants further assert, citing Figures 9 and 10, pages 16-17, and pages 27-28, that these cells also differentiate into cells expressing neurofilament and can form adipose tissue. However, these arguments do not address the new matter rejection. There is no evidence demonstrating support for a CD146-positive cell that has the ability to undergo 140 population doublings.

At pages 10-11 of the response, Applicants assert that the claimed cell populations and clonal cell are distinct from the cells disclosed in the prior art of record. No art rejections are made against the present claims.

Conclusion

No claims are allowable.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic

Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Marie Falk whose telephone number is (571) 272-0728. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras, can be reached on (571) 272-4517. The central official fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

/Anne-Marie Falk/
Primary Examiner, Art Unit 1632